Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 21 (2005), Issue 4, Pages 199-202

Clinical Application of Rapid Assay of Interleukin-6 in Influenza-Associated Encephalopathy

Mikage Nakamura,1 Gaku Yamanaka,1 Hisashi Kawashima,1 Yoshiaki Watanabe,1 Hiroaki Ioi,1 Yasuyo Kashiwagi,1 Kouji Takekuma,1 Akinori Hoshika,1 Mizuho Hayakawa,2 and Shigeru Suzuki2

1Department of Paediatrics, Tokyo Medical University, Japan
2Department of Central Clinical Laboratory, Tokyo Medical University, Japan

Received 5 January 2006; Accepted 5 January 2006

Copyright © 2005 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The characteristics of influenza-associated encephalopathy is the high mortality and nimble progress with coma which appears in general cases within 48 hours. Most of patients show no abnormalities in the standard blood checks on admission or in early stage. In this study we investigated if a rapid assay of interleukin (IL)-6 is useful in influenza-associated encephalopathy in early stages. The levels of IL-6 in patients with influenza-associated encephalopathy did not show any significant difference compared with those in patients with febrile convulsion and rotavirus-associated convulsion. However the levels of IL-6 in severe cases were significantly higher than those of mild cases with influenza-associated encephalopathy. Consequently the rapid assay of serum IL-6 is useful to evaluate and decide the therapies.